The US Food and Drug Administration started 2025 with just more than 60 novel candidates under review, according to the Pink Sheet US FDA Performance Tracker’s User Fee Goal Dates tracker.
Three novel approvals already have been granted, along with
More Coverage
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?